SIPONIMOD
( DrugBank: Siponimod / KEGG DRUG: Siponimod fumarate, Siponimod )
2 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 13 | 多発性硬化症／視神経脊髄炎 | 53 |
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 50 | 皮膚筋炎／多発性筋炎 | 8 |
13. 多発性硬化症／視神経脊髄炎
臨床試験数 : 3,685 / 薬物数 : 1,932 - (DrugBank : 355) / 標的遺伝子数 : 263 - 標的パスウェイ数 : 237
Showing 1 to 10 of 53 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2023-000142-42-IT (EUCTR) | 17/04/202320230417 | 30/01/202320230130 | Exploring the effect of a novel therapy on chronic intrathecal inflammation in patients with active progressive multiple sclerosis Exploring the effect of a novel therapy on chronic intrathecal inflammation in patients with active ... | Exploring the effect of a novel therapy on chronic intrathecal inflammation in patients with active progressive multiple sclerosis - Exploring the effect of a novel therapy on intrathecal inflammation in patients with MS Exploring the effect of a novel therapy on chronic intrathecal inflammation in patients with active ... | patients with secondary progressive MS MedDRA version: 21.1;Level: PT;Classification code 10053395;Term: Progressive multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] patients with secondary progressive MS MedDRA version: 21.1;Level: PT;Classification code 10053395;T ... | Trade Name: Mayzent 2 mg compresse rivestite con film Product Name: Mayzent 2 mg compresse rivestite con film Product Code: [Siponimod 2 mg] INN or Proposed INN: Siponimod fumarato Trade Name: Mayzent 0,25 mg compresse rivestite con film Product Name: Mayzent 0,25 mg compresse rivestite con film Product Code: [Siponimod 0, 25 mg] INN or Proposed INN: Siponimod fumarato Trade Name: Mayzent 2 mg compresse rivestite con film Product Name: Mayzent 2 mg compresse rivestite ... | AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 4 | Italy | ||
| 2 | NCT05376579 (ClinicalTrials.gov) | June 17, 202220220617 | 12/5/202220220512 | Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy | Impact of Mayzent (Siponimod) on Active Secondary Progressive Multiple Sclerosis Patients in a Long-term Non-interventional Study in Italy Impact of Mayzent (Siponimod) on Active Secondary Progressive Multiple Sclerosis Patients in a Long- ... | Active Secondary Progressive Multiple Sclerosis | Other: siponimod | Novartis Pharmaceuticals | NULL | Active, not recruiting | 18 Years | 60 Years | All | 134 | Italy | |
| 3 | NCT04933552 (ClinicalTrials.gov) | December 15, 202120211215 | 18/6/202120210618 | Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzen ... | Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent (Siponimod): An OTIS Observational Pregnancy Surveillance Study Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzen ... | Multiple Sclerosis | Other: Siponimod | Novartis Pharmaceuticals | NULL | Recruiting | N/A | N/A | Female | 867 | United States | |
| 4 | EUCTR2020-002700-39-HR (EUCTR) | 29/11/202120211129 | 06/12/202120211206 | Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis. Efficacy and safety of ofatumumab and siponimodcompared to fingolimod in pediatric patients with mul ... | A 2-year randomized, 3-arm, double-blind, non-inferiority study comparing the efficacy and safety of ofatumumab and siponimod versus fingolimod in pediatric patients with multiple sclerosis followed by an open-label extension. Additional PIP decision number: P/014/2021 - NEOS A 2-year randomized, 3-arm, double-blind, non-inferiority study comparing the efficacy and safety of ... | Multiple Sclerosis in pediatric patients MedDRA version: 20.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Multiple Sclerosis in pediatric patients MedDRA version: 20.1;Level: PT;Classification code 10028245 ... | Trade Name: Kesimpta Product Name: ofatumumab Product Code: OMB157 INN or Proposed INN: OFATUMUMAB Trade Name: Mayzent Product Code: BAF312 INN or Proposed INN: Siponimod Other descriptive name: SIPONIMOD FUMARIC ACID Product Name: Siponimod Product Code: BAF312 INN or Proposed INN: Siponimod Other descriptive name: SIPONIMOD FUMARIC ACID Product Name: Siponimod Product Code: BAF312 INN or Proposed INN: Siponimod Other descriptive name: SIPONIMOD FUMARIC ACID Trade Name: Mayzent Product Code: BAF312 INN or Proposed INN: Siponimod Trade Name: Kesimpta Product Name: ofatumumab Product Code: OMB157 INN or Proposed INN: OFATUMUMAB Trade ... | Novartis Pharma AG | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 3 | Russian Federation;Czechia;United States;Portugal;Austria;Latvia;Guatemala;Brazil;Poland;Slovakia;Chile;Serbia;Lithuania;France;Croatia;Argentina;Romania;Ukraine;United Kingdom;India;Spain;Canada;Turkey;Belgium;Taiwan;Mexico;Italy;Israel;Australia;Germany;Estonia Russian Federation;Czechia;United States;Portugal;Austria;Latvia;Guatemala;Brazil;Poland;Slovakia;Ch ... | ||
| 5 | NCT04895202 (ClinicalTrials.gov) | November 19, 202120211119 | 17/5/202120210517 | Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Study | Swiss Study of the Impact of Mayzent (Siponimod) on Secondary Progressive Multiple Sclerosis Patients in a Long-term Non-interventional Study Swiss Study of the Impact of Mayzent (Siponimod) on Secondary Progressive Multiple Sclerosis Patient ... | Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity | Other: Siponimod | Novartis Pharmaceuticals | NULL | Terminated | 18 Years | N/A | All | 8 | Switzerland | |
| 6 | EUCTR2020-005947-22-IT (EUCTR) | 17/11/202120211117 | 12/10/202120211012 | Effect of siponimod on progressive multiple sclerosis | Effect of siponimod on relevant imaging and immunological hallmarks of progressive multiple sclerosis - Effect of siponimod on progressive multiple sclerosis Effect of siponimodon relevant imaging and immunological hallmarks of progressive multiple sclerosis ... | Active progressive MS course after an initial relapse clinical course MedDRA version: 21.1;Level: PT;Classification code 10053395;Term: Progressive multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Active progressive MS course after an initial relapse clinical course MedDRA version: 21.1;Level: PT ... | Product Name: Siponimod 2 mg Product Code: [Siponimod] INN or Proposed INN: Siponimod Product Name: Siponimod 0,25 mg Product Code: [Siponimod] INN or Proposed INN: Siponimod Product Name: Siponimod 1 mg Product Code: [Siponimod] INN or Proposed INN: Siponimod Product Name: Siponimod2 mg Product Code: [Siponimod] INN or Proposed INN: Siponimod Product Name: Sipo ... | AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA | NULL | Not Recruiting | Female: yes Male: yes | 60 | Phase 4 | Italy | ||
| 7 | NCT04925557 (ClinicalTrials.gov) | November 13, 202120211113 | 24/5/202120210524 | Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis | Open-label, Single-blind, Observational, Comparative, Prospective, 36-month, Longitudinal, Controlled Study to Assess Efficacy of Siponimod (Mayzent®) on Microglia in Patients With Active Secondary Progressive Forms of Multiple Sclerosis Open-label, Single-blind, Observational, Comparative, Prospective, 36-month, Longitudinal, Controlle ... | Secondary-progressive Multiple Sclerosis | Drug: Mayzent;Drug: Ocrevus | State University of New York at Buffalo | NULL | Completed | 18 Years | 60 Years | All | 18 | Phase 2/Phase 3 | United States |
| 8 | NCT04926818 (ClinicalTrials.gov) | October 5, 202120211005 | 14/6/202120210614 | Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis Efficacy and Safety of Ofatumumab and SiponimodCompared to Fingolimod in Pediatric Patients With Mul ... | A 2-year Randomized, 3-arm, Double-blind, Non-inferiority Study Comparing the Efficacy and Safety of Ofatumumab and Siponimod Versus Fingolimod in Pediatric Patients With Multiple Sclerosis Followed by an Open-label Extension A 2-year Randomized, 3-arm, Double-blind, Non-inferiority Study Comparing the Efficacy and Safety of ... | Multiple Sclerosis (MS) | Drug: Fingolimod;Drug: Ofatumumab;Drug: Siponimod;Other: Fingolimod placebo;Other: Siponimod placebo;Other: Ofatumumab placebo Drug: Fingolimod;Drug: Ofatumumab;Drug: Siponimod;Other: Fingolimod placebo;Other: Siponimodplacebo; ... | Novartis Pharmaceuticals | NULL | Active, not recruiting | 10 Years | 17 Years | All | 129 | Phase 3 | United States;Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Mexico;Poland;Portugal;Serbia;Slovakia;Spain;Taiwan;Turkey;Romania;Russian Federation;United Kingdom United States;Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Estonia;France;Germany ... |
| 9 | EUCTR2020-002700-39-SK (EUCTR) | 04/10/202120211004 | 16/06/202120210616 | Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis. Efficacy and safety of ofatumumab and siponimodcompared to fingolimod in pediatric patients with mul ... | A 2-year randomized, 3-arm, double-blind, non-inferiority study comparing the efficacy and safety of ofatumumab and siponimod versus fingolimod in pediatric patients with multiple sclerosis followed by an open-label extension. Additional PIP decision number: P/014/2021 - NEOS A 2-year randomized, 3-arm, double-blind, non-inferiority study comparing the efficacy and safety of ... | Multiple Sclerosis in pediatric patients MedDRA version: 20.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Multiple Sclerosis in pediatric patients MedDRA version: 20.1;Level: PT;Classification code 10028245 ... | Trade Name: Kesimpta Product Name: ofatumumab Product Code: OMB157 INN or Proposed INN: OFATUMUMAB Trade Name: Mayzent Product Code: BAF312 INN or Proposed INN: Siponimod Other descriptive name: SIPONIMOD FUMARIC ACID Product Name: Siponimod Product Code: BAF312 INN or Proposed INN: Siponimod Other descriptive name: SIPONIMOD FUMARIC ACID Product Name: Siponimod Product Code: BAF312 INN or Proposed INN: Siponimod Other descriptive name: SIPONIMOD FUMARIC ACID Trade Name: Mayzent Product Code: BAF312 INN or Proposed INN: Siponimod Trade Name: Kesimpta Product Name: ofatumumab Product Code: OMB157 INN or Proposed INN: OFATUMUMAB Trade ... | Novartis Pharma AG | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 3 | Russian Federation;United States;Czechia;Portugal;Austria;Latvia;Guatemala;Brazil;Poland;Slovakia;Chile;Serbia;France;Lithuania;Croatia;Argentina;Romania;Ukraine;United Kingdom;India;Spain;Canada;Belgium;Taiwan;Mexico;Italy;Israel;Australia;Türkiye;Germany;Estonia Russian Federation;United States;Czechia;Portugal;Austria;Latvia;Guatemala;Brazil;Poland;Slovakia;Ch ... | ||
| 10 | EUCTR2020-002700-39-PL (EUCTR) | 29/09/202120210929 | 10/08/202120210810 | Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis. Efficacy and safety of ofatumumab and siponimodcompared to fingolimod in pediatric patients with mul ... | A 2-year randomized, 3-arm, double-blind, non-inferiority study comparing the efficacy and safety of ofatumumab and siponimod versus fingolimod in pediatric patients with multiple sclerosis followed by an open-label extension. Additional PIP decision number: P/014/2021 - NEOS A 2-year randomized, 3-arm, double-blind, non-inferiority study comparing the efficacy and safety of ... | Multiple Sclerosis in pediatric patients MedDRA version: 20.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Multiple Sclerosis in pediatric patients MedDRA version: 20.1;Level: PT;Classification code 10028245 ... | Trade Name: Kesimpta Product Name: ofatumumab Product Code: OMB157 INN or Proposed INN: OFATUMUMAB Trade Name: Mayzent Product Code: BAF312 INN or Proposed INN: Siponimod Other descriptive name: SIPONIMOD FUMARIC ACID Product Name: Siponimod Product Code: BAF312 INN or Proposed INN: Siponimod Other descriptive name: SIPONIMOD FUMARIC ACID Product Name: Siponimod Product Code: BAF312 INN or Proposed INN: Siponimod Other descriptive name: SIPONIMOD FUMARIC ACID Trade Name: Mayzent Product Code: BAF312 INN or Proposed INN: Siponimod Trade Name: Kesimpta Product Name: ofatumumab Product Code: OMB157 INN or Proposed INN: OFATUMUMAB Trade ... | Novartis Pharma AG | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 3 | Germany;Estonia;Russian Federation;United States;Czechia;Portugal;Austria;Latvia;Poland;Guatemala;Brazil;Slovakia;Chile;Serbia;France;Lithuania;Croatia;Argentina;Romania;Ukraine;United Kingdom;India;Spain;Canada;Belgium;Taiwan;Mexico;Italy;Israel;Australia;Türkiye Germany;Estonia;Russian Federation;United States;Czechia;Portugal;Austria;Latvia;Poland;Guatemala;Br ... |
50. 皮膚筋炎／多発性筋炎
臨床試験数 : 231 / 薬物数 : 216 - (DrugBank : 55) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 141
Showing 1 to 8 of 8 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2012-002859-42-BE (EUCTR) | 16/10/201420141016 | 25/08/201420140825 | Study of efficacy and tolerability for BAF312 compared to placebo in patients with polymyositis | A multi-centre, double-blind, placebo controlled, proof of concept study to evaluate the efficacy and tolerability of BAF312 in patients with polymyositis A multi-centre, double-blind, placebo controlled, proof of concept study to evaluate the efficacy an ... | Polymyositis MedDRA version: 18.0;Level: PT;Classification code 10036102;Term: Polymyositis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Polymyositis MedDRA version: 18.0;Level: PT;Classification code 10036102;Term: Polymyositis;System O ... | Product Name: BAF312 0.25 mg tablet Product Code: BAF312X INN or Proposed INN: Siponimid Other descriptive name: BAF312 hemifumarate Product Name: BAF312 1 mg tablet Product Code: BAF312X INN or Proposed INN: Siponimod Other descriptive name: BAF312 hemifumarate Product Name: BAF312 2 mg tablet Product Code: BAF312X INN or Proposed INN: Siponimod Other descriptive name: BAF312 hemifumarate Product Name: BAF312 0,5 mg tablet Product Code: BAF312X INN or Proposed INN: Siponimod Other descriptive name: BAF312 hemifumarate Product Name: BAF312 0.25 mg tablet Product Code: BAF312X INN or Proposed INN: Siponimid Other descript ... | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 45 | Phase 2 | United States;Hungary;Czech Republic;Taiwan;Canada;Poland;Belgium | ||
| 2 | EUCTR2013-001799-39-BE (EUCTR) | 16/10/201420141016 | 02/09/201420140902 | Study of efficacy and tolerability for BAF312 compared to placebo in patients with active dermatomyositis. Study of efficacy and tolerability for BAF312 compared to placebo in patients with active dermatomyo ... | A double blind, randomized, placebo-controlled study to evaluate, safety, tolerability, efficacy and preliminary dose-response of BAF312 in patients with active dermatomyositis. - safety and efficacy of BAF312 in dermatomyositis A double blind, randomized, placebo-controlled study to evaluate, safety, tolerability, efficacy and ... | Active dermatomyositis MedDRA version: 18.0;Level: PT;Classification code 10012503;Term: Dermatomyositis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Active dermatomyositis MedDRA version: 18.0;Level: PT;Classification code 10012503;Term: Dermatomyos ... | Product Code: BAF312 INN or Proposed INN: Siponimod Other descriptive name: BAF312 hemifumarate Product Code: BAF312 INN or Proposed INN: Siponimod Other descriptive name: BAF312 hemifumarate Product Code: BAF312 INN or Proposed INN: Siponimod Other descriptive name: BAF312 hemifumarate Product Code: BAF312 INN or Proposed INN: Siponimod Other descriptive name: BAF312 hemifumarate Product Code: BAF312 INN or Proposed INN: Siponimod Other descriptive name: BAF312 hemifumarate Product ... | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 56 | Phase 2 | United States;Hungary;Czech Republic;Taiwan;Canada;Poland;Belgium;Germany;Japan | ||
| 3 | EUCTR2013-001799-39-PL (EUCTR) | 15/02/201420140215 | 13/01/201420140113 | Study of efficacy and tolerability for BAF312 compared to placebo in patients with active dermatomyositis. Study of efficacy and tolerability for BAF312 compared to placebo in patients with active dermatomyo ... | A double blind, randomized, placebo-controlled study to evaluate, safety, tolerability, efficacy and preliminary dose-response of BAF312 in patients with active dermatomyositis. A double blind, randomized, placebo-controlled study to evaluate, safety, tolerability, efficacy and ... | Active dermatomyositis MedDRA version: 17.0;Level: PT;Classification code 10012503;Term: Dermatomyositis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Active dermatomyositis MedDRA version: 17.0;Level: PT;Classification code 10012503;Term: Dermatomyos ... | Product Code: BAF312 INN or Proposed INN: Siponimod Other descriptive name: BAF312 hemifumarate | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 56 | United States;Hungary;Czech Republic;Canada;Poland;Germany;Japan | |||
| 4 | EUCTR2013-001799-39-CZ (EUCTR) | 19/12/201320131219 | 08/10/201320131008 | Study of efficacy and tolerability for BAF312 compared to placebo in patients with active dermatomyositis. Study of efficacy and tolerability for BAF312 compared to placebo in patients with active dermatomyo ... | A double blind, randomized, placebo-controlled study to evaluate, safety, tolerability, efficacy and preliminary dose-response of BAF312 in patients with active dermatomyositis. A double blind, randomized, placebo-controlled study to evaluate, safety, tolerability, efficacy and ... | Active dermatomyositis MedDRA version: 18.1;Level: PT;Classification code 10012503;Term: Dermatomyositis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Active dermatomyositis MedDRA version: 18.1;Level: PT;Classification code 10012503;Term: Dermatomyos ... | Product Code: BAF312 0.25 mg INN or Proposed INN: Siponimod Other descriptive name: BAF312 hemifumarate Product Code: BAF312 0.5 mg INN or Proposed INN: Siponimod Other descriptive name: BAF312 hemifumarate Product Code: BAF312 1 mg INN or Proposed INN: Siponimod Other descriptive name: BAF312 hemifumarate Product Code: BAF312 2 mg INN or Proposed INN: Siponimod Other descriptive name: BAF312 hemifumarate Product Code: BAF312 0.25 mg INN or Proposed INN: Siponimod Other descriptive name: BAF312 hemifumarat ... | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 56 | United States;Hungary;Czech Republic;Canada;Poland;Germany;Japan | |||
| 5 | EUCTR2013-001799-39-HU (EUCTR) | 26/09/201320130926 | 08/08/201320130808 | Study of efficacy and tolerability for BAF312 compared to placebo in patients with active dermatomyositis. Study of efficacy and tolerability for BAF312 compared to placebo in patients with active dermatomyo ... | A double blind, randomized, placebo-controlled study to evaluate, safety, tolerability, efficacy and preliminary dose-response of BAF312 in patients with active dermatomyositis. - safety and efficacy of BAF312 in dermatomyositis A double blind, randomized, placebo-controlled study to evaluate, safety, tolerability, efficacy and ... | Active dermatomyositis MedDRA version: 18.0;Level: PT;Classification code 10012503;Term: Dermatomyositis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Active dermatomyositis MedDRA version: 18.0;Level: PT;Classification code 10012503;Term: Dermatomyos ... | Product Code: BAF312 0.25 mg INN or Proposed INN: Siponimod Other descriptive name: BAF312 hemifumarate Product Code: BAF312 0.50 mg INN or Proposed INN: Siponimod Other descriptive name: BAF312 hemifumarate Product Code: BAF312 1mg INN or Proposed INN: Siponimod Other descriptive name: BAF312 hemifumarate Product Code: BAF312 2mg INN or Proposed INN: Siponimod Other descriptive name: BAF312 hemifumarate Product Code: BAF312 0.25 mg INN or Proposed INN: Siponimod Other descriptive name: BAF312 hemifumarat ... | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 56 | United States;Czech Republic;Taiwan;Hungary;Canada;Poland;Belgium;Netherlands;Germany;Japan;China;Switzerland United States;Czech Republic;Taiwan;Hungary;Canada;Poland;Belgium;Netherlands;Germany;Japan;China;Sw ... | |||
| 6 | EUCTR2012-002859-42-PL (EUCTR) | 23/05/201320130523 | 04/02/201320130204 | Efficacy and tolerability for BAF312 in patients with polymyositis | A multi-centre, double-blind, placebo controlled, proof of concept study to evaluate the efficacy and tolerability of BAF312 in patients with polymyositis A multi-centre, double-blind, placebo controlled, proof of concept study to evaluate the efficacy an ... | Polymyositis MedDRA version: 19.0;Level: PT;Classification code 10036102;Term: Polymyositis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Polymyositis MedDRA version: 19.0;Level: PT;Classification code 10036102;Term: Polymyositis;System O ... | Product Name: Siponimod 0.25 mg tablet Product Code: BAF312X INN or Proposed INN: Siponimod Other descriptive name: BAF312 hemifumarate Product Name: Siponimod 1 mg tablet Product Code: BAF312X INN or Proposed INN: Siponimod Other descriptive name: BAF312 hemifumarate Product Name: Siponimod 2 mg Tablet Product Code: BAF312X INN or Proposed INN: Siponimod Other descriptive name: BAF312 hemifumarate Product Name: Siponimod 0.5 mg tablet Product Code: BAF312X INN or Proposed INN: Siponimod Other descriptive name: BAF312 hemifumarate Product Name: Siponimod0.25 mg tablet Product Code: BAF312X INN or Proposed INN: Siponimod Other descri ... | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 45 | Phase 2 | United States;Hungary;Czech Republic;Taiwan;Canada;Belgium;Poland;Switzerland | ||
| 7 | EUCTR2012-002859-42-CZ (EUCTR) | 20/02/201320130220 | 18/12/201220121218 | Study of efficacy and tolerability for BAF312 compared to placebo in patients with polymyositis | A multi-centre, double-blind, placebo controlled, proof of concept study to evaluate the efficacy and tolerability of BAF312 in patients with polymyositis A multi-centre, double-blind, placebo controlled, proof of concept study to evaluate the efficacy an ... | Polymyositis MedDRA version: 19.0;Level: PT;Classification code 10036102;Term: Polymyositis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Polymyositis MedDRA version: 19.0;Level: PT;Classification code 10036102;Term: Polymyositis;System O ... | Product Name: BAF312 0.25 mg tablet Product Code: BAF312X INN or Proposed INN: Siponimid Other descriptive name: BAF312 hemifumarate Product Name: BAF312 1 mg tablet Product Code: BAF312X INN or Proposed INN: Siponimod Other descriptive name: BAF312 hemifumarate Product Name: BAF312 0.25 mg tablet Product Code: BAF312X INN or Proposed INN: Siponimid Other descript ... | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 45 | Phase 2 | United States;Hungary;Czech Republic;Canada;Belgium;Poland | ||
| 8 | EUCTR2012-002859-42-HU (EUCTR) | 25/01/201320130125 | 05/11/201220121105 | Study of efficacy and tolerability for BAF312 compared to placebo in patients with polymyositis | A multi-centre, double-blind, placebo controlled, proof of concept study to evaluate the efficacy and tolerability of BAF312 in patients with polymyositis A multi-centre, double-blind, placebo controlled, proof of concept study to evaluate the efficacy an ... | Polymyositis MedDRA version: 14.1;Level: PT;Classification code 10036102;Term: Polymyositis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Polymyositis MedDRA version: 14.1;Level: PT;Classification code 10036102;Term: Polymyositis;System O ... | Product Name: BAF312 0.25 mg tablet Product Code: BAF312X INN or Proposed INN: Siponimid Other descriptive name: BAF312 hemifumarate Product Name: BAF312 1 mg tablet Product Code: BAF312X INN or Proposed INN: Siponimod Other descriptive name: BAF312 hemifumarate Product Name: BAF312 0.25 mg tablet Product Code: BAF312X INN or Proposed INN: Siponimid Other descript ... | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 30 | Phase 2 | United States;Czech Republic;Hungary;Canada;Belgium;Poland |